Prescription Required.Why?
Proxetil is the active ingredient in most cefpodoxime formulations. it's a cephalosporin antibiotic.
Treatment of bacterial infections of the respiratory tract (e.g., bronchitis, pneumonia)
Treatment of skin and skin structure infections
Treatment of ear infections (otitis media)
Treatment of urinary tract infections
Safepod 100mg Susp 30ml (Cefpodoxime) proxetil is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis. This prevents the bacteria from multiplying and ultimately leads to their destruction.
Store Cefpodoxime at room temperature, away from moisture and direct sunlight. Keep out of reach of children. Discard any unused medication after the expiration date.
Dosage depends on the specific infection being treated and the patient's age and health status. Always follow your doctor's instructions.
Cefpodoxime is typically administered orally (as tablets, capsules, or suspension).
Complete the full course of antibiotics even if symptoms improve to prevent recurrence of infection.
Diarrhea
Nausea
Vomiting
Abdominal pain
Headache
Rash
Vaginal yeast infection (candidiasis)
Alcohol consumption may be restricted or avoided while taking Cefpodoxime, especially in patients with pre-existing liver conditions. Consult your physician.
Cefpodoxime generally doesn't affect alertness, but if side effects like dizziness or drowsiness occur, avoid operating machinery or driving.
Use only if the potential benefits outweigh the potential risks. Consult your doctor before using Cefpodoxime during pregnancy or breastfeeding.
Dosage adjustments may be needed for children. Consult your pediatrician.
Patients with kidney disease may require dose adjustments. Your doctor will determine the appropriate dosage based on your kidney function.
Patients with liver disease may require dose adjustments. Close monitoring by your doctor is essential.
Consult your doctor or pharmacist for further information. Refer to the medication's package insert for detailed prescribing information.
